MA argues for patents
October 17, 2012
THE newly announced review into
the appropriateness of the extension
arrangements for pharmaceutical
patents (PD yest) should consider
the “compelling case to extend the
patent life of innovative medicines”,
according to Medicines Australia.
“Given it takes as long as three
years to get a new medicine listed
on the PBS, and rejection rates by
the PBAC are increasing, it’s timely
to look at whether patent terms are
long enough,” said CE of Medicines
Australia, Dr Brendan Shaw.
“In light of some of the recent
deterioration we have seen in
patent protection in some
countries, the review provides the
opportunity for the Australian
Government to give a clear signal
about its approach to intellectual
property to those countries and to
Australian technology companies,”
Shaw added.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Oct 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Oct 12
